Podcasts

Industry, innovation & Viagra-stuffed teddies at AAPS

Industry, innovation & Viagra-stuffed teddies at AAPS

By Nick Taylor & Mike Stones

Last week everything from co-processed excipients to Viagra-stuffed teddies were discussed at AAPS 2010. Now, with the show having finished, we present our personal take on the event.

Recipharm's new facility in Parets, Spain

Global reach key for CDMOs, says Recipharm CEO

By Gareth Macdonald and Claire Videau

Recipharm says changes to Big Pharma and drug industry globalisation make having a worldwide manufacturing reach a virtual necessity for CDMOs.

Regulatory expert insight: electronic submission

Regulatory expert insight: electronic submission

By Gareth Macdonald and Claire Videau

Adoption of electronic submission by regulators around the world is good news for drugmakers’ efforts to access emerging markets says industry expert Kate Wilber.

eClinical talks future of data management

eClinical talks future of data management

By Alexandria Pešić and Claire Videau

Clinical data management is, and will continue to be a key concern for the pharmaceutical industry, according to Susan Bornstein, executive vice president of eClinical solutions, who discussed the issue with Outsourcing-pharma earlier this week.

Regulatory expert insight: Regulatory information management

Industry view

Regulatory expert insight: Regulatory information management

By Gareth Macdonald

Tracking “non-content” metadata is an important part of any pharmaceutical submission, yet many drugmakers fail to take an integrated approach to the task according to regulatory expert Kate Wilber.

KCAS talks biomarker strategy development

KCAS talks biomarker strategy development

By Claire Videau and Gareth Macdonald

Biomarkers are critical to discovery and can help pharmaceutical firms make development a more efficient and cost effective process accord to bioanalysis services provider KCAS.

Almac Diagnostics discusses new biomarker service

Almac Diagnostics discusses new biomarker service

By Gareth Macdonald

Almac says an effective biomarker strategy boosts a drug candidates’ chance of success and can ultimately add value to a developer’s business by opening door to diagnostics.